首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Modulation of mismatch repair and genomic stability by miR-155
【24h】

Modulation of mismatch repair and genomic stability by miR-155

机译:miR-155对错配修复和基因组稳定性的调节

获取原文
获取原文并翻译 | 示例
       

摘要

Inactivation of mismatch repair (MMR) is the cause of the common cancer predisposition disorder Lynch syndrome (LS), also known as hereditary nonpolyposis colorectal cancer (HNPCC), as well as 10-40% of sporadic colorectal, endometrial, ovarian, gastric, and uro-thelial cancers. Elevated mutation rates (mutator phenotype), including simple repeat instability [microsatellite instability (MSI)] are a signature of MMR defects. MicroRNAs (miRs) have been implicated in the control of critical cellular pathways involved in development and cancer. Here we show that overexpression of miR-155 significantly down-regulates the core MMR proteins, hMSH2, hMSH6, and hMLH1, inducing a mutator phenotype and MSI. An inverse correlation between the expression of miR-155 and the expression of MLH1 or MSH2 proteins was found in human colorectal cancer. Finally, a number of MSI tumors with unknown cause of MMR inactivation displayed miR-155 overexpression. These data provide support for miR-155 modulation of MMR as a mechanism of cancer pathogenesis.
机译:失配修复(MMR)失活是常见的癌症易患性疾病Lynch综合征(LS),也称为遗传性非息肉病性结直肠癌(HNPCC),以及散发性结直肠癌,子宫内膜癌,卵巢癌,胃癌,和尿路上皮癌。升高的突变率(突变体表型),包括简单的重复不稳定性[微卫星不稳定性(MSI)]是MMR缺陷的标志。 MicroRNA(miRs)已参与控制与发育和癌症有关的关键细胞途径。在这里,我们显示miR-155的过表达显着下调了核心MMR蛋白,hMSH2,hMSH6和hMLH1,从而诱导了突变体表型和MSI。在人类结直肠癌中发现了miR-155的表达与MLH1或MSH2蛋白的表达呈负相关。最后,许多MMR失活原因未知的MSI肿瘤显示miR-155过表达。这些数据为MMR-155调节MMR作为癌症发病机理提供了支持。

著录项

  • 来源
  • 作者单位

    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH 43210 Department of Embryology and Morphology, University of Ferrara, Ferrara 44121, Italy;

    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH 43210;

    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH 43210 lstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola 47014, Italy;

    Department of Internal Medicine, Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH 43210;

    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH 43210;

    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH 43210;

    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH 43210;

    lstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola 47014, Italy;

    lstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola 47014, Italy;

    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH 43210;

    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH 43210;

    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH 43210;

    Department of Pathology, Ohio State University Medical Center, Columbus, OH 43210;

    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH 43210;

    Department of Experimental and Diagnostic Medicine, University of Ferrara, Ferrara 44121, Italy;

    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH 43210;

    Department of Experimental and Diagnostic Medicine, University of Ferrara, Ferrara 44121, Italy;

    Department of Experimental and Diagnostic Medicine, University of Ferrara, Ferrara 44121, Italy;

    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH 43210 Department of Embryology and Morphology, University of Ferrara, Ferrara 44121, Italy;

    Department of Experimental and Diagnostic Medicine, University of Ferrara, Ferrara 44121, Italy;

    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH 43210;

    lstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola 47014, Italy;

    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH 43210 Department of Physics, Ohio State University, Columbus, OH 43210;

    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH 43210 Department of Experimental and Diagnostic Medicine, University of Ferrara, Ferrara 44121, Italy;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    colorectal cancer; DNA repair; microRNA;

    机译:大肠癌;DNA修复;微小RNA;
  • 入库时间 2022-08-18 00:41:19

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号